After-hours movers: Levi, Greenbrier, Aehr Test and more By Investing.com

Levi reported net revenue of $1.7B, up 14% reported and 9% organic vs Q1 2025, and shares rose ~6% after hours. Skillsoft jumped ~25% on quarter (total revenue $131M), while Aehr missed Q3 revenue at $10.3M vs $10.8M consensus (-3% share move) and Insmed fell ~2% after discontinuing its hidradenitis suppurativa program following a failed trial. Greenbrier missed top- and bottom-line estimates, fell ~5%, and trimmed FY2026 delivery expectations (shifted into early FY2027) while planning double-digit lease-fleet growth and higher fleet investment to boost recurring revenue.

Analysis

Consumer staples with strong brand pull and high gross-margin apparel franchises stand to capture squeezes in inventory-to-sales normalization; these businesses can convert modest top-line acceleration into outsized free cash flow within two to three quarters via fixed-cost leverage and lower promo intensity. Expect a lumpy but front-loaded benefit to EBIT margins as wholesale order cadence stabilizes, which should amplify buyback optionality and raise takeover optionality for strategically cash-rich acquirers.

In transportation and capital-equipment pockets, timing shifts create an earnings deferral rather than demand destruction — but that deferral is meaningful for market multiple resets. Companies increasing leased-asset footprints will trade like growth-at-a-cost stories: short-term FCF dilution in exchange for higher recurring revenue, which pushes meaningful valuation bifurcation between near-term EPS-focused investors and yield/recurring-revenue investors over the next 6–18 months.

Biotech binary risk remains acute after program cessation: the market typically overshoots on headline failure, compressing the implied probability of alternative value-capture paths (partnerships, platform monetization, M&A) well below realistic takeover math when cash runway exceeds 9–12 months. Semiconductor test-equipment misses signal inventory rebalancing at small fabs — a rebound tied to AI-driven capex could arrive within 2–4 quarters, making current weakness a timing, not necessarily structural, issue.

Key Decisions for Investors

• Long LEVI (1–3% NAV, 6–9 month horizon): accumulate on any <=10% pullback, target +25–35% vs stop -15%. Rationale: margin leverage and buyback optionality make upside convex; hedge with 3–6 month out-of-the-money puts if worried about macro-linked retail derates.
• Pair trade — Long LEVI / Short GBX (equal notional, 3–6 month horizon): play consumer margin recovery vs revenue-deferral/lease-capex drag at transportation OEMs. Expect spread appreciation of 20–30%; cut if GBX signals improved delivery cadence or LEVI traffic materially softens.
• Short AEHR (0.5–1% NAV, 2–3 month horizon) or buy puts to define risk: trade the near-term capex weakness while keeping position size small for binary recovery if AI/data-center spend reaccelerates. Target 20–40% return; hard stop at +25% adverse move.
• Long SKIL (1–2% NAV, 9–12 month horizon): buy LEAPS or 12-month calls to capture subscription/recurring revenue multiple expansion. Target +30% upside driven by multiple re-rating; downside limited to premium paid, consider selling short-dated calls to lower cost.
• Event-sized biotech hedge on INSM (<=0.25% NAV in option skews): either avoid outright or buy deep OTM longer-dated calls as asymmetric M&A optionality if cash runway >9 months; alternatively buy short-dated puts if you need to protect portfolio biotech exposure — expect high volatility and binary outcomes.